⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BDRX News
Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group
globenewswire.com
BDRX
ADR Ratio Change
globenewswire.com
BDRX
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
globenewswire.com
BDRX
Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
accessnewswire.com
BDRX
GSK
PFE
NVS
COGT
Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST
globenewswire.com
BDRX
Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary
globenewswire.com
BDRX
Biodexa Announces Pricing of $10 Million Public Offering
globenewswire.com
BDRX
Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP
globenewswire.com
BDRX
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
globenewswire.com
BDRX
Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion
globenewswire.com
BDRX